Fred Hutch Researchers Engineer Complex Immunotherapy That May Target Relapsing Leukemia – Newswise (press release)
|
Fred Hutch Researchers Engineer Complex Immunotherapy That May Target Relapsing Leukemia
Newswise (press release) The findings, published online in the journal Blood, provide the basis for launching a first-in-human clinical trial of this new immunotherapy, which relies on engineered T-cell receptors, or TCRs. This immunotherapy represents a different method of … |
